Compare Stocks: ASMB, SLGL, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$20.41 +1.1%	$23.55	$19.20 ▼ $39.71	$414.96M	1.26	195,065 shs	92,282 shs
NKTR Nektar Therapeutics	$38.28 +2.8%	$49.26	$33.40 ▼ $109.00	$1.30B	1.44	1.06 million shs	104,588 shs
SLGL Sol-Gel Technologies	$55.02 -2.2%	$66.95	$32.51 ▼ $97.97	$180.07M	1.25	40,564 shs	4,534 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-9.79%	+0.90%	-0.79%	-38.76%	-43.71%
NKTR Nektar Therapeutics	-3.10%	+3.04%	-1.77%	-48.99%	-35.41%
SLGL Sol-Gel Technologies	-11.28%	-10.73%	-17.64%	-33.58%	+81.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$20.41 +1.1%	$23.55	$19.20 ▼ $39.71	$414.96M	1.26	195,065 shs	92,282 shs
NKTR Nektar Therapeutics	$38.28 +2.8%	$49.26	$33.40 ▼ $109.00	$1.30B	1.44	1.06 million shs	104,588 shs
SLGL Sol-Gel Technologies	$55.02 -2.2%	$66.95	$32.51 ▼ $97.97	$180.07M	1.25	40,564 shs	4,534 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-9.79%	+0.90%	-0.79%	-38.76%	-43.71%
NKTR Nektar Therapeutics	-3.10%	+3.04%	-1.77%	-48.99%	-35.41%
SLGL Sol-Gel Technologies	-11.28%	-10.73%	-17.64%	-33.58%	+81.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.50	Moderate Buy	$46.50	127.87% Upside
NKTR Nektar Therapeutics	2.69	Moderate Buy	$130.67	241.38% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$197.50	258.95% Upside

Current Analyst Ratings Breakdown

Latest ASMB, SLGL, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	ASMB Assembly Biosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
11/3/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$52.00 ➝ $48.00
10/19/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
10/15/2026	ASMB Assembly Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SLGL Sol-Gel Technologies	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/14/2026	SLGL Sol-Gel Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Neutral	$53.00
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/12/2026	NKTR Nektar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$130.00
10/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$178.00
10/9/2026	NKTR Nektar Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	5.75	N/A	N/A	$13.04 per share	1.56
NKTR Nektar Therapeutics	$55.23M	23.66	N/A	N/A	$4.41 per share	8.68
SLGL Sol-Gel Technologies	$19.39M	9.28	N/A	N/A	$8.19 per share	6.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	19.98	408.12	N/A	-0.06%	-0.02%	-0.02%	N/A
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	N/A

Latest ASMB, SLGL, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ASMB Assembly Biosciences	-$0.6550	-$0.93	-$0.2750	-$0.93	$9.07 million	$2.96 million
11/12/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.07	-$1.63	+$0.44	-$1.63	$10.27 million	$9.39 million
11/12/2026	Q3 2026	SLGL Sol-Gel Technologies	-$2.07	-$1.72	+$0.35	-$1.72	$0.15 million	$0.04 million
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
NKTR Nektar Therapeutics	N/A	10.42	10.42
SLGL Sol-Gel Technologies	N/A	10.37	10.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
NKTR Nektar Therapeutics	75.88%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
NKTR Nektar Therapeutics	2.50%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
SLGL Sol-Gel Technologies	28	3.27 million	1.10 million	No Data

ASMB, SLGL, and NKTR Headlines

Recent News About These Companies

Sol-Gel Technologies (NASDAQ:SLGL) Releases Earnings Results, Beats Estimates By $0.35 EPS

November 12 at 1:25 PM | marketbeat.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates

November 12 at 10:41 AM | zacks.com

Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

November 12 at 8:30 AM | globenewswire.com

Sol-Gel Technologies (SLGL) Projected to Release Earnings on Thursday

November 12 at 2:26 AM | americanbankingnews.com

Sol-Gel Technologies (SLGL) Set to Post Earnings on Thursday

November 12 at 2:25 AM | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Stock Now Rated "Buy" by Wall Street Brokerages

October 26, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Stock Rating Reaffirmed as Buy by HC Wainwright

October 19, 2026 | marketbeat.com

Head to Head Analysis: Sol-Gel Technologies (NASDAQ:SLGL) vs. Trulieve Cannabis (NYSE:TRLV)

October 18, 2026 | defenseworld.netD

Sol-Gel Technologies (NASDAQ:SLGL) Upgraded at Zacks Research

October 17, 2026 | marketbeat.com

New Strong Buy Stocks for October 16th

October 16, 2026 | zacks.com

Cantor Fitzgerald initiates coverage of Sol-Gel Technologies at overweight

October 14, 2026 | msn.com

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

October 14, 2026 | marketbeat.com

Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day Transcript

October 14, 2026 | seekingalpha.com

Sol-Gel Technologies (NASDAQ:SLGL) Now Covered by Analysts at Cantor Fitzgerald

October 14, 2026 | marketbeat.com

SolGel Technologies (SLGL) Upgraded to Buy: Here's Why

October 8, 2026 | zacks.com

Sol-Gel Technologies consensus price target decreased by 22.46% to $155.55

October 2, 2026 | msn.com

Sol-Gel Technologies Sets October 14 KOL Investor Day for SGT-610

September 30, 2026 | tipranks.com

Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026

September 30, 2026 | globenewswire.com

SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

September 17, 2026 | zacks.com

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

September 17, 2026 | globenewswire.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys $98,448.42 in Stock

September 15, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, SLGL, and NKTR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$20.41 +0.23 (+1.12%)

As of 10:39 AM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Nektar Therapeutics NASDAQ:NKTR

$38.28 +1.03 (+2.75%)

As of 10:39 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sol-Gel Technologies NASDAQ:SLGL

$55.02 -1.23 (-2.18%)

As of 10:37 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, SLGL, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, SLGL, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, SLGL, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, SLGL, and NKTR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Nektar Therapeutics NASDAQ:NKTR

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, SLGL, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, SLGL, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, SLGL, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, SLGL, and NKTR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Nektar Therapeutics NASDAQ:NKTR

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools